Jagsonpal Q3 FY23 revenues grew by 11.6% to Rs. 60.1 Cr; PAT up by 47.1%
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
SEEDS is a mnemonic for Shun Tobacco, Eat Correctly, Exercise Regularly, Dump obesity and excess alcohol, and Stay vigilant about your family history aims at making more and more people aware about the tenets of cancer prevention
With the on-going relentless efforts to imbibe new developments in ART, India will make significant progress in ensuring the best facilities and care for fertility to couples in India
A pharma industry veteran with over three decades of experience in domestic as well as international markets
The company is proud to be at the forefront of promoting cancer awareness and hopes to make a positive impact on the lives of its employees
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
Subscribe To Our Newsletter & Stay Updated